Portable Transcranial Stimulation Device Global Market Report 2025

The portable transcranial stimulation device market size has grown rapidly in recent years. It will grow from $1.24 billion in 2024 to $1.37 billion in 2025 at a compound annual growth rate (CAGR) of 10.2%. The growth during the historic period can be attributed to the rising prevalence of neurological disorders, increased awareness of non-invasive brain stimulation therapies, growing demand for home-based therapeutic solutions, a global rise in mental health issues, the development of healthcare infrastructure in emerging economies, and the expansion of clinical research activities.

The portable transcranial stimulation device market size is expected to see strong growth in the next few years. It will grow to $1.99 billion in 2029 at a compound annual growth rate (CAGR) of 9.9%. The growth during the forecast period can be attributed to the increasing focus on personalized brain health solutions, rising investments in neurorehabilitation programs, a growing elderly population experiencing cognitive decline, an increase in government initiatives promoting mental wellness, the expansion of outpatient neurotherapy centers, and the rising preference for portable therapeutic devices. Key trends in the forecast period include technological progress in compact and wearable stimulation systems, improvements in user-friendly interface design, innovations in multi-modal stimulation functions, advancements in remote monitoring and app-based therapy integration, research and development in adaptive stimulation algorithms, and enhancements in the safety and precision of stimulation delivery.

The increasing prevalence of neurological and psychiatric disorders is anticipated to drive the growth of the portable transcranial stimulation device market in the coming years. Neurological and psychiatric disorders affect the brain and nervous system, resulting in alterations in thinking, emotions, or behavior. The increase in these disorders is largely associated with chronic stress, which disrupts brain chemistry and neural function, reducing mental resilience and heightening vulnerability to such conditions. Portable transcranial stimulation devices influence brain activity through low-intensity electrical currents directed at specific regions, enhancing neural connectivity and function to help relieve symptoms of neurological and psychiatric disorders in a non-invasive and accessible way. For example, in October 2023, the World Federation of Neurology, a UK-based association of national neurological societies, reported that over 40% of the global population currently experiences some form of neurological condition, with this figure expected to nearly double by 2050. Therefore, the growing prevalence of neurological and psychiatric disorders is fueling the expansion of the portable transcranial stimulation device market.

Leading companies in the portable transcranial stimulation device market are emphasizing the development of advanced products such as transcranial direct current stimulation (tDCS) devices to offer non-invasive and user-friendly solutions for both home and clinical use. Transcranial direct current stimulation (tDCS) devices are non-invasive instruments that deliver low-intensity electrical currents to targeted brain regions to regulate neuronal activity, enhance cognitive functions, and support the management of neurological and psychiatric conditions. For instance, in October 2023, Sooma Oy, a Finland-based medical device manufacturer, introduced Sooma Duo, a portable tDCS-based brain stimulation device designed to provide clinician-prescribed neuromodulation therapies for conditions such as depression and chronic pain. The device features remote clinician monitoring, preset electrode positioning, and automatic resistance control, improving treatment adherence, therapeutic results, and accessibility of brain stimulation therapies in home and clinical settings.

In March 2025, Lindus Health, a UK-based contract research organization, collaborated with Sooma Medical to conduct a pivotal phase 3 clinical trial evaluating Sooma’s wearable transcranial direct current stimulation (tDCS) cap, Sooma 2GEN, as a home-based treatment for major depressive disorder (MDD). This partnership aims to produce comprehensive safety and efficacy data in real-world remote conditions, expedite regulatory approval, and promote the broader commercialization of Sooma’s portable brain stimulation platform. Sooma Medical is a Finland-based manufacturer of portable transcranial stimulation devices.

Major players in the portable transcranial stimulation device market are Neurocare Group AG, G.Tec Medical Engineering, Neurosoft Ltd., Neuroelectrics Barcelona S.L.U., Salvia BioElectronics B.V., Flow Neuroscience AB, Soterix Medical Inc., RPW Technology LLC, Sooma Medical Inc., Ybrain Co. Ltd., Remed Co. Ltd., Fisher Wallace Laboratories Inc., Nexalin Technology Inc., Caputron LLC, Mind Alive Inc., Ionclinics GmbH, NeuroEM Therapeutics Inc., NeuroSigma Inc., PlatoScience Inc., and TheBrainDriver GmbH.

North America was the largest region in the portable transcranial stimulation device market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in portable transcranial stimulation device report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The fast surge in U.S. tariffs and the trade tensions that followed in spring 2025 are heavily affecting the medical equipment sector, particularly for imported imaging machine components, surgical-grade stainless steel, and plastic disposables. Hospitals and clinics resist price hikes, pressuring manufacturers’ margins. Regulatory hurdles compound the problem, as tariff-related supplier changes often require re-certification of devices, delaying time-to-market. Companies are mitigating risks by dual-sourcing critical parts, expanding domestic production of commoditized items, and accelerating R&D in cost-efficient materials.

The portable transcranial stimulation device market research report is one of a series of new reports that provides portable transcranial stimulation device market statistics, including portable transcranial stimulation device industry global market size, regional shares, competitors with a portable transcranial stimulation device market share, detailed portable transcranial stimulation device market segments, market trends and opportunities, and any further data you may need to thrive in the portable transcranial stimulation device industry. The portable transcranial stimulation device market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The portable transcranial stimulation device is a compact and mobile unit designed to deliver targeted electrical or magnetic stimulation to the brain to influence neural activity. It improves cognitive and neurological functions through precise, non-invasive treatment. Its portable structure ensures convenience and ease of use, allowing users to receive therapy at any time and place. The device also provides consistent and controlled stimulation, supporting effective neurological outcomes.

The main product categories of portable transcranial stimulation devices include transcranial direct current stimulation (tDCS) devices, transcranial magnetic stimulation (TMS) devices, and others. Transcranial direct current stimulation (tDCS) devices are portable tools that deliver low-intensity electrical currents to specific brain regions to alter neuronal activity for therapeutic or cognitive improvement. These devices are available through both online and offline distribution channels and are applied in areas such as depression, anxiety, pain management, cognitive enhancement, and others. They are used by various end users, including hospitals and clinics, home care environments, research institutes, and others.

The countries covered in the portable transcranial stimulation device market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The portable transcranial stimulation device market consists of sales of stimulation headbands, wearable stimulation caps, handheld stimulators, electrode patches, rechargeable battery packs, stimulation kits, and electrode gels. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.